Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of irinotecan hydrochloride liposome injection II in Chinese patients with gastrointestinal tumors
ChiCTR2500106246Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Shanxi Medical University
- Start
- Jul 2025
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of liposomal irinotecan in gastric cancer (GC), colorectal cancer (CRC), pancreatic cancer (PC) and 2 more, sponsored by First Affiliated Hospital of Shanxi Medical University. Primary endpoint: Incidence of adverse reactions. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
liposomal irinotecan
03
Conditions
gastric cancer (GC)colorectal cancer (CRC)pancreatic cancer (PC)esophageal cancergastrointestinal cancer
Beyond the preview
Go deeper on ChiCTR2500106246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106246.